KCL PATHWAYS: The Diagnostic Shell Game

How a trial designed to look like science institutionalises medical transition

The PATHWAYS Trial (IRAS 1011645) is presented as the study that will finally answer the Cass Review’s central question: does GnRHa alleviate gender-related distress?

It isn't. A forensic and time-consuming examination of the 122 page thicket intended to obfuscate its true purpose reveals a different picture — a regulatory manoeuvre built on three sleights of hand:

1. It exploits the shift from Gender Dysphoria to Gender Incongruence to sidestep the need to prove distress is alleviated at all.

2. It replaces a genuine efficacy test with a methodology to support medical transition — a design that all but guarantees a “positive” result.

3. It uses an open-label extension as a backdoor to move GnRHa from off-label to on-label use for gender incongruence.

Each is worth unpacking on its own.

---

1. The diagnostic bait-and-switch

DSM-5 Gender Dysphoria requires clinically significant distress or impairment to daily functioning — a mandatory threshold, and the basis on which the UK’s Gender Recognition Service operates. ICD-11 Gender Incongruence requires only a persistent sense of incongruence plus a desire to transition — no distress threshold, and deliberately classified as a sexual health condition rather than a psychiatric one, following sustained WPATH lobbying to remove the “disorder” framing.

PATHWAYS recruits on the second definition, not the first. That single choice does most of the trial’s work:

• Cass’s own review relied on the York Systematic Review (Taylor et al., 2024), which analysed the Utrecht Gender Dysphoria Scale (UGDS) — a distress-based measure. PATHWAYS relegates UGDS to a secondary outcome, quietly avoiding the metric York found insufficient evidence for.

• King’s College London frames recruitment around incongruence (identity) but measures success with KIDSCREEN-10, a generic quality-of-life scale with no gender- or body-related items. Identity affirmation and distress alleviation are different clinical questions, and PATHWAYS conflates them.

• Cass’s own findings (para. 82) note that no changes in gender dysphoria or body satisfaction were demonstrated in the underlying evidence base — the very outcome PATHWAYS’s design now avoids re-testing.

The protocol is explicit about the recruitment criterion: section 3.2.1.2 specifies diagnosis “according to ICD-11,” with no mention of distress.

Put plainly: Cass asked whether GnRHa alleviates gender-related distress in children with Gender Dysphoria. PATHWAYS asks whether transition improves generic wellbeing in children with Gender Incongruence. Different question, and one that’s far easier to answer “yes” to.

---

2. The efficacy shell game

PATHWAYS is framed as testing GnRHa’s efficacy. In practice, both trial arms are already on the same transition pathway — they just start GnRHa at different times. The comparator arm (HORIZON INTENSIVE) involves no transition anticipation, which flatters the treatment arms by contrast, and there is no no-treatment arm at all, so the trial cannot isolate what GnRHa itself contributes versus what merely anticipating transition contributes.

What actually gets measured, in effect, is anticipation of transition — not pharmacological benefit. That’s a design that manufactures a positive result rather than tests for one. The protocol lays out the structure in section 2.2 (immediate vs. delayed GnRHa, both arms on the pathway) and section 3.3.2 (the comparator’s lack of transition anticipation), and confirms in section 13.7 that there are no interim analyses for futility or efficacy — nothing that could stop the trial early if the drug weren’t working.

---

3. The licensing backdoor

GnRHa remains off-label for gender incongruence. PATHWAYS appears designed to generate just enough data to change that. The open-label extension application is due at Month 12 — before primary endpoint data has even been collected (protocol §1.6.5). That locks in continued access regardless of what the trial eventually finds, creating a precedent for on-label use while sidestepping the risk that the primary data comes back negative. Section 4.7 describes how the extension entrenches the pathway from GnRHa through to cross-sex hormones.

---

The cumulative effect

None of these three design choices is damning alone. Together, they mean the trial can barely fail. Recruiting on Gender Incongruence removes the distress threshold; a generic wellbeing scale as primary outcome all but guarantees a favourable result; the absence of a no-treatment arm means GnRHa’s actual effect is never isolated; and the Month-12 open-label extension secures continued, and eventually licensed, access before any of that data is even in.

The population this reaches is also far broader than Cass envisaged. Cass suggested transition might be appropriate for a small minority with severe, lifelong distress. Recruiting on ICD-11 criteria — incongruence plus a desire to transition, no distress required — opens the trial to a considerably larger group.

And it’s public money doing this: a £10 million budget that looks structured to generate data supporting an existing clinical pathway, rather than to rigorously test a hypothesis that could fail.

---

Final verdict

PATHWAYS presents as a scientific study addressing the Cass Review’s concerns. Look beyond the smoke and mirrors to discover a regulatory manoeuvre — one that licenses GnRHa for gender incongruence rather than dysphoria, institutionalises the pathway from puberty blockers to cross-sex hormones, and expands access to a population far broader than Cass ever envisaged.

This is not science. It is activism dressed up as research.

Version History

Version 1: 18 July 2026